Protocol Ledger

NCT05793892 · Phase III · COMPLETED

Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults

Interventional Phase III clinical trial protocol NCT05793892 sponsored by Cutia Therapeutics(Wuxi)Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-06 Enrollment: 286 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05793892
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)286 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05793892
Protocol FieldVerified Registry Value
NCT IdentifierNCT05793892
Consolidated Lead SponsorCutia Therapeutics(Wuxi)Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment286 participants (ACTUAL)
Registered Start Date2023-04-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI